LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 2002 and is based in Beijing, China.
Company profile
Ticker
LSB, LSBPW
Exchange
Website
CEO
Mr. Wang Xu
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
YishengBio Co., Ltd, YS Biopharma Co., Ltd.
SEC CIK
LSB stock data
Latest filings (excl ownership)
6-K
Report of Foreign Private Issuer
8 Oct 24
6-K
LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation
27 Sep 24
6-K/A
Current report (foreign) (amended)
10 Sep 24
6-K
Report of Foreign Private Issuer
10 Sep 24
6-K
LakeShore Biopharma Announces Leadership Transitions
4 Sep 24
6-K
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024
15 Aug 24
20-F
2024 FY
Annual report (foreign)
15 Aug 24
NT 20-F
Notice of late annual filing (foreign)
31 Jul 24
6-K
Report of Foreign Private Issuer
5 Jul 24
6-K
Report of Foreign Private Issuer
18 Jun 24
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Mar 23 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Mar 24 | Mar 23 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q2 2024
13F holders | Current |
---|---|
Total holders | 37 |
Opened positions | 32 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 3.61 bn |
Total shares | 147.38 mm |
Total puts | 0.00 |
Total calls | 1.19 mm |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Wong Fung Ching | 98.36 mm | $39.44 mm |
Zhang /MD Yi | 38.97 mm | $15.75 mm |
Orbimed Advisors | 1.40 mm | $909.83 mm |
FMR | 1.17 mm | $754.85 mm |
LMR Partners | 1.05 mm | $92.62 mm |
Hillhouse Capital Advisors | 751.79 k | $487.09 mm |
Valliance Asset Management | 750.00 k | $66.00 mm |
FIL | 733.42 k | $475.19 mm |
BFAM Partners | 550.00 k | $37.46 mm |
Jane Street | 498.30 k | $43.85 mm |